Logistic regression models of associations between intensive blood pressure treatment, mediators (major adverse cardiovascular events or serious adverse events), and mortalitya
| Variable . | OR (95% CI) . |
|---|---|
| Mediator: MACE, outcome: all-cause mortality | |
| Intensive BP treatment-MACE (Pathway 1) | 0.80 (0.67–0.97) |
| MACE-all-cause mortality (Pathway 2) | 4.98 (3.80–6.54) |
| Intensive BP treatment-all-cause mortality (Pathway 3) | 0.73 (0.59–0.90) |
| Mediator: MACE, outcome: CV mortality | |
| Intensive BP treatment-MACE (Pathway 1) | 0.80 (0.67–0.96) |
| MACE-CV mortality (Pathway 2) | 16.3 (10.6–25.1) |
| Intensive BP treatment-CV mortality (Pathway 3) | 0.57 (0.38–0.85) |
| Mediator: MACE, outcome: non-CV mortality | |
| Intensive BP treatment-MACE (Pathway 1) | 0.80 (0.67–0.96) |
| MACE-non-CV mortality (Pathway 2) | 2.11 (1.45–3.06) |
| Intensive BP treatment-non-CV mortality (Pathway 3) | 0.81 (0.63–1.04) |
| Mediator: SAE, outcome: all-cause mortality | |
| Intensive BP treatment-SAE (Pathway 1) | 1.28 (1.14–1.43) |
| SAE-all-cause mortality (Pathway 2) | 1.88 (1.47–2.39) |
| Intensive BP treatment-all-cause mortality (Pathway 3) | 0.73 (0.59–0.90) |
| Mediator SAE, outcome: CV mortality | |
| Intensive BP treatment-SAE (Pathway 1) | 1.28 (1.14–1.43) |
| SAE-CV mortality (Pathway 2) | 1.19 (0.74–1.93) |
| Intensive BP treatment-CV mortality (Pathway 3) | 0.57 (0.38–0.85) |
| Mediator: SAE, outcome: non-CV mortality | |
| Intensive BP treatment-SAE (Pathway 1) | 1.28 (1.14–1.43) |
| SAE-non-CV mortality (Pathway 2) | 2.14 (1.63–2.82) |
| Intensive BP treatment-non-CV mortality (Pathway 3) | 0.81 (0.63–1.04) |
| Variable . | OR (95% CI) . |
|---|---|
| Mediator: MACE, outcome: all-cause mortality | |
| Intensive BP treatment-MACE (Pathway 1) | 0.80 (0.67–0.97) |
| MACE-all-cause mortality (Pathway 2) | 4.98 (3.80–6.54) |
| Intensive BP treatment-all-cause mortality (Pathway 3) | 0.73 (0.59–0.90) |
| Mediator: MACE, outcome: CV mortality | |
| Intensive BP treatment-MACE (Pathway 1) | 0.80 (0.67–0.96) |
| MACE-CV mortality (Pathway 2) | 16.3 (10.6–25.1) |
| Intensive BP treatment-CV mortality (Pathway 3) | 0.57 (0.38–0.85) |
| Mediator: MACE, outcome: non-CV mortality | |
| Intensive BP treatment-MACE (Pathway 1) | 0.80 (0.67–0.96) |
| MACE-non-CV mortality (Pathway 2) | 2.11 (1.45–3.06) |
| Intensive BP treatment-non-CV mortality (Pathway 3) | 0.81 (0.63–1.04) |
| Mediator: SAE, outcome: all-cause mortality | |
| Intensive BP treatment-SAE (Pathway 1) | 1.28 (1.14–1.43) |
| SAE-all-cause mortality (Pathway 2) | 1.88 (1.47–2.39) |
| Intensive BP treatment-all-cause mortality (Pathway 3) | 0.73 (0.59–0.90) |
| Mediator SAE, outcome: CV mortality | |
| Intensive BP treatment-SAE (Pathway 1) | 1.28 (1.14–1.43) |
| SAE-CV mortality (Pathway 2) | 1.19 (0.74–1.93) |
| Intensive BP treatment-CV mortality (Pathway 3) | 0.57 (0.38–0.85) |
| Mediator: SAE, outcome: non-CV mortality | |
| Intensive BP treatment-SAE (Pathway 1) | 1.28 (1.14–1.43) |
| SAE-non-CV mortality (Pathway 2) | 2.14 (1.63–2.82) |
| Intensive BP treatment-non-CV mortality (Pathway 3) | 0.81 (0.63–1.04) |
See Figure 1. The exposure variable intensive BP was randomized. Mediator–mortality pathways were adjusted for treatment intensity, age, number of BP medications, smoking, sex, glomerular filtration, aspirin and statin use, race, body mass index, cardiovascular disease, glucose, total and HDL-cholesterol, triglycerides. BP, blood pressure; MACE, major adverse cardiovascular events; SAE, serious adverse events.
Logistic regression models of associations between intensive blood pressure treatment, mediators (major adverse cardiovascular events or serious adverse events), and mortalitya
| Variable . | OR (95% CI) . |
|---|---|
| Mediator: MACE, outcome: all-cause mortality | |
| Intensive BP treatment-MACE (Pathway 1) | 0.80 (0.67–0.97) |
| MACE-all-cause mortality (Pathway 2) | 4.98 (3.80–6.54) |
| Intensive BP treatment-all-cause mortality (Pathway 3) | 0.73 (0.59–0.90) |
| Mediator: MACE, outcome: CV mortality | |
| Intensive BP treatment-MACE (Pathway 1) | 0.80 (0.67–0.96) |
| MACE-CV mortality (Pathway 2) | 16.3 (10.6–25.1) |
| Intensive BP treatment-CV mortality (Pathway 3) | 0.57 (0.38–0.85) |
| Mediator: MACE, outcome: non-CV mortality | |
| Intensive BP treatment-MACE (Pathway 1) | 0.80 (0.67–0.96) |
| MACE-non-CV mortality (Pathway 2) | 2.11 (1.45–3.06) |
| Intensive BP treatment-non-CV mortality (Pathway 3) | 0.81 (0.63–1.04) |
| Mediator: SAE, outcome: all-cause mortality | |
| Intensive BP treatment-SAE (Pathway 1) | 1.28 (1.14–1.43) |
| SAE-all-cause mortality (Pathway 2) | 1.88 (1.47–2.39) |
| Intensive BP treatment-all-cause mortality (Pathway 3) | 0.73 (0.59–0.90) |
| Mediator SAE, outcome: CV mortality | |
| Intensive BP treatment-SAE (Pathway 1) | 1.28 (1.14–1.43) |
| SAE-CV mortality (Pathway 2) | 1.19 (0.74–1.93) |
| Intensive BP treatment-CV mortality (Pathway 3) | 0.57 (0.38–0.85) |
| Mediator: SAE, outcome: non-CV mortality | |
| Intensive BP treatment-SAE (Pathway 1) | 1.28 (1.14–1.43) |
| SAE-non-CV mortality (Pathway 2) | 2.14 (1.63–2.82) |
| Intensive BP treatment-non-CV mortality (Pathway 3) | 0.81 (0.63–1.04) |
| Variable . | OR (95% CI) . |
|---|---|
| Mediator: MACE, outcome: all-cause mortality | |
| Intensive BP treatment-MACE (Pathway 1) | 0.80 (0.67–0.97) |
| MACE-all-cause mortality (Pathway 2) | 4.98 (3.80–6.54) |
| Intensive BP treatment-all-cause mortality (Pathway 3) | 0.73 (0.59–0.90) |
| Mediator: MACE, outcome: CV mortality | |
| Intensive BP treatment-MACE (Pathway 1) | 0.80 (0.67–0.96) |
| MACE-CV mortality (Pathway 2) | 16.3 (10.6–25.1) |
| Intensive BP treatment-CV mortality (Pathway 3) | 0.57 (0.38–0.85) |
| Mediator: MACE, outcome: non-CV mortality | |
| Intensive BP treatment-MACE (Pathway 1) | 0.80 (0.67–0.96) |
| MACE-non-CV mortality (Pathway 2) | 2.11 (1.45–3.06) |
| Intensive BP treatment-non-CV mortality (Pathway 3) | 0.81 (0.63–1.04) |
| Mediator: SAE, outcome: all-cause mortality | |
| Intensive BP treatment-SAE (Pathway 1) | 1.28 (1.14–1.43) |
| SAE-all-cause mortality (Pathway 2) | 1.88 (1.47–2.39) |
| Intensive BP treatment-all-cause mortality (Pathway 3) | 0.73 (0.59–0.90) |
| Mediator SAE, outcome: CV mortality | |
| Intensive BP treatment-SAE (Pathway 1) | 1.28 (1.14–1.43) |
| SAE-CV mortality (Pathway 2) | 1.19 (0.74–1.93) |
| Intensive BP treatment-CV mortality (Pathway 3) | 0.57 (0.38–0.85) |
| Mediator: SAE, outcome: non-CV mortality | |
| Intensive BP treatment-SAE (Pathway 1) | 1.28 (1.14–1.43) |
| SAE-non-CV mortality (Pathway 2) | 2.14 (1.63–2.82) |
| Intensive BP treatment-non-CV mortality (Pathway 3) | 0.81 (0.63–1.04) |
See Figure 1. The exposure variable intensive BP was randomized. Mediator–mortality pathways were adjusted for treatment intensity, age, number of BP medications, smoking, sex, glomerular filtration, aspirin and statin use, race, body mass index, cardiovascular disease, glucose, total and HDL-cholesterol, triglycerides. BP, blood pressure; MACE, major adverse cardiovascular events; SAE, serious adverse events.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
